Press Releases

Please Select Year

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer

Dec 13, 2022

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Oct 14, 2022

Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule

Jun 30, 2022

Novartis provides update on production of radioligand therapy medicines

May 5, 2022

Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

Mar 23, 2022

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Sep 28, 2021

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Sep 17, 2021

Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Jun 23, 2021

Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Jun 16, 2021

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Jun 3, 2021

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Jun 3, 2021

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Mar 30, 2021

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Mar 23, 2021

Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis

Jun 30, 2020

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours

Apr 7, 2020

We inform you that the personal data you provide by sending this e-mail will be processed in compliance with ARTICLES 13 AND 14 OF REGULATION (EU) 2016/679 (GDPR) as referred to in the privacy policy on our website and which recalls the confidentiality obligations that inspire our company’s activity in order to be able to respond quickly and comprehensively to your request.

The processing of your personal data will be carried out using appropriate tools to ensure the security and confidentiality of the aforementioned data.

The methods of processing of data referred in this notice to here provide for applies for the use of manual, computerized and telematic tools.

Your data will be processed by employees and / or collaborators of AAA duly appointed for processing. Furthermore, AAA is part of a multinational Group, therefore it may be that your personal data are transferred to other countries, even outside the European Union, to parent companies, subsidiaries or affiliates, as well as to external service companies, even if only for technical-IT reasons. In these cases we will proceed to their transfer only in the presence of the provision of your consent.

The optional, explicit and voluntary sending of e-mail address or other data entered in the contact form to the official addresses indicated on this site entails the subsequent acquisition of the sender’s e-mail address necessary to respond to requests, as well as any other personal data entered. Specific summary information could be progressively reported or displayed on the pages of the website prepared for particular services on request.

The user confers the widest indemnity with respect to any objection, claim request for compensation for damage from treatment that should be received by the Data Controller from any third party concerned due to the provision of data indicated by the user in violation of the rules on protection of the personal data applicable according to the GDPR 2016/679.

THE REGULATION (EU) 2016/679 includes measures to protect and guarantee your rights, in particular, the interested party has the right at any time to obtain confirmation of the existence of personal data concerning him/her and to know its content and origin, verify its accuracy or request its integration or updating, or rectification. It also has the right to request the cancellation, transformation into anonymous form or blocking of data processed in violation of the law, as well as to oppose in any case, for legitimate reasons, to their processing. You may exercise these rights at any time by contacting us at: dataprivacy.aaa@novartis.com.

To get more information about the website Privacy Policy, CLICK HERE.